Back

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma

2025-04-19 hematology Title + abstract only
View on medRxiv
Show abstract

DIRECT was a prospective, multisite study assessing the feasibility and utility of circulating tumor DNA (ctDNA) in 188 patients with aggressive B-cell non-Hodgkin lymphoma using a lymphoma-customized assay and open-source pipeline. CtDNA fraction assessed by copy number alterations in pre-treatment plasma identified high-risk patients more effectively than existing clinical risk scores. In 74.5% of cases ctDNA was equivalent or superior to biopsy for genetic profiling. Patients not suitable for...

Predicted journal destinations